Travere Therapeutics (TVTX) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -10.84% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 26.38% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 34.98% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Travere Therapeutics | 4.34 Bn | 4.26 Bn | 102.38 Mn | -27.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.01% |
| Dec 31, 2025 | 7.65% |
| Dec 31, 2024 | 25.99% |
| Sep 30, 2024 | 88.17% |
| Jun 30, 2024 | 73.13% |
| Mar 31, 2024 | 87.59% |
| Dec 31, 2023 | 76.51% |
| Sep 30, 2023 | 132.96% |
| Jun 30, 2023 | 37.95% |
| Mar 31, 2023 | 133.09% |
| Dec 31, 2022 | 38.47% |
| Sep 30, 2022 | 33.79% |
| Jun 30, 2022 | 32.68% |
| Mar 31, 2022 | 28.88% |
| Dec 31, 2021 | -128.36% |
| Sep 30, 2021 | 13.21% |
| Jun 30, 2021 | -20.44% |
| Mar 31, 2021 | -43.10% |
| Dec 31, 2020 | -90.41% |
| Sep 30, 2020 | -8.21% |
| Jun 30, 2020 | -25.37% |
| Mar 31, 2020 | 27.50% |
| Dec 31, 2019 | -52.08% |
| Sep 30, 2019 | 0.56% |
| Jun 30, 2019 | -42.40% |
| Mar 31, 2019 | -78.14% |
| Dec 31, 2018 | -44.54% |
| Sep 30, 2018 | -36.02% |
| Jun 30, 2018 | 4.36% |
| Mar 31, 2018 | -35.06% |
| Dec 31, 2017 | 15.33% |
| Sep 30, 2017 | 0.35% |
| Jun 30, 2017 | -46.13% |
| Mar 31, 2017 | 47.29% |
| Dec 31, 2016 | 12.28% |
| Sep 30, 2016 | -45.65% |
| Jun 30, 2016 | -39.63% |
| Mar 31, 2016 | 62.66% |